UrologyNews.net

Urology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

The results from the final analysis of the phase 3 TITAN study, which has demonstrated the continued statistically significant benefit of Apalutamide ( Erleada ) plus androgen deprivation therapy ( AD ...


The American Cancer Society estimates that in 2020, there will have been more than 190,000 cases of prostate cancer in the U.S. One of the treatment options for advanced prostate cancer is androgen ...


The results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201, were presented. The cohort is evaluating the antibody-drug conjugate Enfortumab vedoti ...


Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic castration-resistant prostate cancer ( mCRPC ) and whose t ...


Apalutamide in combination with ADT prolonged median overall survival by 14 months and decreased the risk of death by 22%. Median overall survival was significantly longer, with 73.9 months for p ...


Pre‐clinical studies have suggested that Metformin and statins may delay prostate cancer metastases; however, data in humans are limited. This is the first human study aimed to quantify the individu ...


Initial results from the phase 1 clinical trial EV-103 were announced. Forty-five patients were evaluated for safety with the combination of the investigational agent Enfortumab Vedotin and the immune ...


Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy ( BKI ) released a study investigating the use of combination checkpoint immunotherapy ...


For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a higher likelihood of being diagnosed with Alzheimer's disease or dementia, compared to ...


Although bladder cancer is a fairly rare cancer type, representing an estimated 4.6% of new cancer cases in 2019, it is the most common malignancy of the urinary system, with high recurrence rate and ...


Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical Oncology (ASCO ) Annual Meeting in Chicago, and simultaneously published in The New England ...


Activation of FGFR signaling is involved in a variety of malignancies including advanced urothelial cancer. Rogaratinib is an oral pan-FGFR kinase inhibitor. Results from a phase I expansion co ...


ADXS-PSA, an attenuated Listeria monocytogenes-based immunotherapy that targets prostate-specific antigen ( PSA ), is designed to generate antigen-specific T cell effectors that kill tumor cells. Pu ...


Anti-PD1 treatment with Pembrolizumab ( Keytruda ) is a promising treatment strategy in many solid tumors. Researchers have reported clinical outcomes of adding Pembrolizumab to men with metastatic ...


Cabozantinib ( Cabometyx ) has shown robust clinical activity in advanced clear cell renal cell carcinoma ( RCC ). Non-clear cell renal cell carcinoma ( nccRCC ), a heterogeneous mix of diseases, ha ...